Nebenwirkungen · Oslif Breezhaler
Oslif Breezhaler 150 microgram inhalation powder, hard capsules Oslif Breezhaler 300 microgram inhalation powder, hard capsules · Abschnitt 4.8 · PDF-Seite 6
HOS-212853 · Präparat HOS-154990
At the recommended doses, the adverse reaction profile of Oslif Breezhaler in patients with COPD shows clinically insignificant systemic effects of beta2-adrenergic stimulation. Mean heart rate changes were less than one beat per minute, and tachycardia was infrequent and reported at a similar rate as under placebo treatment. Relevant prolongations of QTcF were not detectable in comparison to placebo. The frequency of notable QTcF intervals [i.e. >450 ms (males) and >470 ms (females)] and reports of hypokalaemia were similar to placebo. The mean of the maximum changes in blood glucose were similar between Oslif Breezhaler and placebo.
Originalpassage; keine automatisch abgeleitete Schwere, Häufigkeit oder Kausalität. Auch verneinte Befunde und nicht untersuchte Kombinationen bleiben sichtbar.
Vollständigen Kontext in der EMA-Fachinformation lesen →Quellennachweis
Version 2025-11-18T17:00:00Z · SHA-256 18b46cd9126c7d9a7f204bb67d49f1ba5702f381cf921b9f1b5dce688eb9c1ed · Passage bbb72a162c840db072ae50cb87d8ad4e54f2e4bf522d6c6b3fff44b7b8f2f526 · Zeichen 322–964 im Abschnitt